A single antiviral for a triple epidemic: is itpossible?

Aim: A triple epidemic of respiratory syncytial virus (RSV), SARS-CoV-2 and influenza variants is on the

rise worldwide. It is crucial to identify antiviral agents that can be used against all three viruses associatd

with this triple epidemic. Materials & methods: A total of ten antiviral agents were investigated in this

study. Using molecular docking and the molecular mechanics/position-Boltzmann surface area technique,

an examination of the binding affinity and protein–ligand interactions was conducted. Results:Out of the

ten ligands that were compared, three showed the highest affinity for the docking site related to three

the viral infections in descending order: AVG-388, remdesivir and nirmatrelvir. Conclusion: In conclusion,

AVG-388, remdesivir and nirmatrelvir could be recommended as effective antiviral agents during the triple

epidemic.